This discussion will examine the deployment of AI-driven legal tools across IP, regulatory, competition and transactional workflows within life science organisations. The session will explore the strengths and current limitations of machine learning approaches within legal workflows, outline the latest developments in legal task-specific AI software and address how legal teams across practices can move from pilot AI initiatives towards implemented frameworks that boost efficiency and enhance output.

Trade secret protection is becoming an increasingly critical component of life sciences IP strategy, as companies reassess the boundaries between patent protection, regulatory disclosure and confidential know-how. This roundtable will examine how organisations are structuring trade secret frameworks within their wider IP portfolio, and how legal teams are navigating the tension between disclosure requirements and long-term competitive advantage.

From changes to patent systems and licensing to new data exclusivity rules and PTE frameworks, landmark developments across Latin America and APAC are reshaping the global IP and regulatory landscape. This roundtable will examine key jurisdictional updates across these strategically important regions, and explore what key changes mean for your cross-border IP and regulatory strategy.

Deal obligations, such as Commercially Reasonable Effort (CRE), Commercially Diligent Effort (CDE) and “best effort” clauses, play a central role in allocating developmental and commercialisation risk in life science transactions. This discussion will examine how these obligations are defined, managed and enforced, and how teams can mitigate risk exposure under these obligations across collaboration and licensing agreements.

In sensitive, high-value life science transactions, clean rooms require more than technical safeguards; they demand clear governance structures and documented accountability. This discussion will explore how legal teams can design oversight frameworks, define escalation protocols and maintain irreproachable audit trails that withstand third-party scrutiny and post-transaction challenge.

This session examines the legal and structural complexities facing small-to-medium-sized life science companies when pursuing licensing, collaboration, joint venture and M&A agreements with larger, more established players in the market. Participants will examine how life science SMEs can structure transactions strategically to optimise valuation, protect foreground and background IP and retain sufficient governance control to support secondary patent filings and pipeline expansions.

This session examines the legal and governance challenges that arise when life sciences companies engage in joint advocacy through trade associations, industry coalitions and collective policy initiatives. Participants will examine how companies can structure regulatory engagement and industry collaboration to support effective advocacy while implementing appropriate safeguards to prevent anti-competitive coordination.

As the U.S. Patent Trial and Appeal Board (PTAB) recalibrates its approach to discretionary denials under Director Squires' leadership, PTAB strategy is becoming harder to predict and more important to get right. This roundtable will examine how the new standards are playing out in practice and what they mean for challengers and patent owners navigating PTAB proceedings.

This session will examine evolving Environmental, Social and Governance (ESG) obligations affecting the life sciences sector, including the revised Urban Waste Water Treatment Directive and its potential cost-allocation consequences for pharmaceutical manufacturers. Participants will explore the new European ESG legislation and discuss how environmental liability exposure, supply chain transparency requirements and new reporting standards are reshaping risk management frameworks and long-term operational planning across the industry. 

Ongoing amendments and transitional extensions are continuing to reshape the practical implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) across the EU. This session will outline the latest updates to these legislations and explore the persisting uncertainties and challenges for legal teams managing medical device and IVD portfolios.